InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC ...Middle East

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug)...

Hence then, the article about inxmed receives approval to initiate phase i clinical trial in china for omtx705 a first in class fap targeting adc was published today ( Wednesday 30/08/2023 - 06:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC )

Also on site :

• What the US strike in Venezuela means for gas prices and the largest proven oil reserve on the planet
• Ukraine-Russia war latest: Zelensky and Starmer discuss how to spend billions seized from Abramovich after Chelsea sale
• State of emergency declared: Venezuela mobilizes following US airstrikes